Hemab Therapeutics Holdings, Inc. Common Stock

Hemab Therapeutics is a clinical-stage biotech focused on bleeding disorders — the sutacimig program (Glanzmann thrombasthenia) plus HMB-002 in Von Willebrand disease are the two lead assets. It's a recent IPO with no meaningful public trading history yet, but +45% TTM into Aug 20 earnings with multiple clinical catalysts.

• Revenue is zero: Q1 revenue of $0 with -$22M Q1 FCF — the pre-revenue biotech setup where the entire equity value depends on clinical data and future licensing/M&A.
• Cash-rich framing is real: the 'cash-rich coagulation franchise' framing in Seeking Alpha coverage refers to Hemab holding meaningful IPO proceeds — dilution risk is meaningfully lower than most pre-commercial biotechs.
• Multiple clinical catalysts ahead: sutacimig Glanzmann Phase 2 data plus HMB-002 Von Willebrand Phase 1/2 progress — specific dated catalysts that reprice the equity binary on results.
• The rare-bleeding-disorder positioning is a real niche: small patient populations mean lower commercial risk if approved plus premium pricing — the ideal biotech-M&A target profile for a larger pharma.

Setup coils here: an Aug 20 print with cash-runway extension confirmed plus specific catalyst timelines disclosed pulls COAG toward 52-week highs. Absent specific catalyst dates or cash-runway commentary, the tape coils indefinitely — cash-rich pre-revenue biotech doesn't break down without a specific negative.